Ocuphire Pharma Stock Surges After Nyxol Combo Treatment Meets Study Endpoints In Presbyopic Patients

Ocuphire Pharma Inc OCUP announced data from the VEGA-1 Phase 2 trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects.
Presbyopic is the gradual loss of the eye's ability to focus on nearby objects.
61% of subjects treated with Nyxol + LDP improved 15 letters or greater in photopic binocular near vision at 1 hour than 28% of subjects on placebo with statistical significance.
Met the Phase 3 co-primary endpoint vs. placebo gaining 15 letters near vision with less than five letters of distance vision loss.
Rapid onset of efficacy at 30 mins.
Durable near vision improvement through at least 6 hours.
A sustained significant reduction in pupil diameter over at least 18 hours due to the long-lasting effects of Nyxol.
No severe adverse events (AEs) were reported. Almost all AEs were mild. No headaches, no brow aches, and no blurry vision AEs were reported.
Mild, transient conjunctival hyperemia (eye redness) was observed in less than 5% of subjects.
The company plans to initiate Phase 3 trials for presbyopia in 2022 and a second Nyxol Phase 3 trial for Reversal of Mydriasis later this year.
Price Action: OCUP shares are up 66.5% at $7.81 during the premarket session on the last check Wednesday.